Quick Takeaways
- IBRX - ImmunityBio, Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$2,283,602.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 17 Insiders of ImmunityBio, Inc.
- Symbol
- IBRX on Nasdaq
- Location
- San Diego, CA
What Changed
- Buy value: ; sell value: $2,283,601.
- Net share flow: -250,000.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$2,283,602.
Buys
$0
Shares: 0
Insiders: 0
Sells
$2,283,602
Shares: 250,000
Insiders: 2
Net
-$2,283,602
Shares: -250,000
Insiders: -2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 200,000 | $0 | $2,033,602 | -$2,033,602 |
| 3-6 | 0 | 50,000 | $0 | $250,000 | -$250,000 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
ImmunityBio, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Patrick Soon-Shiong | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | $572,512,835 | Mixed | 31 Mar 2026 | ||
| Nant Capital, LLC | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| MP 13 Ventures, LLC | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| Cambridge Equities, LP | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| CALIFORNIA CAPITAL EQUITY, LLC | 10%+ Owner | $571,730,825 | Mixed | 31 Mar 2026 | ||
| Barry J. Simon | Director | $16,909,279 | -$1,783,602 | -9.5% | Mixed | 24 Feb 2026 |
| Richard Adcock | CEO & President, Director | $5,917,675 | Mixed | 22 Feb 2026 | ||
| David C. Sachs | Chief Financial Officer | $2,889,293 | Mixed | 22 Feb 2026 | ||
| John C. Thomas | Former Director | $1,086,143 | Mixed | 31 Dec 2021 | ||
| Regan J. Lauer | Chief Accounting Officer | $1,035,917 | Mixed | 22 Feb 2026 | ||
| Christobel Selecky | Director | $0 | -$500,000 | -100% | Mixed | 23 Feb 2026 |
| Cheryl Cohen | Director | Mixed | 18 Jun 2025 | |||
| Linda Maxwell | Director | Mixed | 18 Jun 2025 | |||
| Bruce Wendel | Director | Mixed | 12 Dec 2025 | |||
| Wesley Clark | Director | Mixed | 18 Jun 2025 | |||
| John Owen Brennan | Director | Mixed | 11 Jun 2024 | |||
| Michael D. Blaszyk | Director | Mixed | 18 Jun 2025 |
Top shareholders of ImmunityBio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cambridge Equities, LP |
13D/G
3/4/5
|
Patrick Soon-Shiong · 10%+ Owner |
66%
|
745,576,456
|
$4,406,356,855 | +$9,487,063 | 23 Feb 2026 | |
| Patrick Soon-Shiong |
3/4/5
|
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
—
mixed-class rows
|
288,867,272
mixed-class rows
|
$572,512,835 | — | 31 Mar 2026 | |
| CALIFORNIA CAPITAL EQUITY, LLC |
3/4/5
|
10%+ Owner |
26%
|
288,752,943
|
$571,730,825 | — | 31 Mar 2026 | |
| MP 13 Ventures, LLC |
3/4/5
|
10%+ Owner |
26%
|
288,752,943
|
$571,730,825 | — | 31 Mar 2026 | |
| Nant Capital, LLC |
3/4/5
|
10%+ Owner |
26%
|
288,752,943
|
$571,730,825 | — | 31 Mar 2026 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.9%
|
32,777,257
|
$64,898,969 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.3%
|
25,601,219
|
$50,690,414 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.5%
|
16,455,703
|
$32,582,292 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
1.3%
|
14,224,224
|
$28,163,963 | — | 31 Dec 2025 | |
| Barry J. Simon |
3/4/5
|
Director |
—
mixed-class rows
|
2,866,066
mixed-class rows
|
$16,909,279 | -$1,783,602 | 24 Feb 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.7%
|
7,920,178
|
$15,684,103 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.55%
|
6,152,684
|
$12,182,314 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.45%
|
5,106,214
|
$10,110,303 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.42%
|
4,717,843
|
$9,341,329 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.32%
|
3,654,499
|
$7,235,908 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.31%
|
3,446,540
|
$6,824,149 | — | 31 Dec 2025 | |
| AlphaCore Capital LLC |
13F
|
Company |
0.27%
|
3,000,544
|
$5,941,077 | — | 31 Dec 2025 | |
| Richard Adcock |
3/4/5
|
CEO & President, Director |
—
mixed-class rows
|
712,783
mixed-class rows
|
$5,917,675 | — | 22 Feb 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
2,501,666
|
$4,953,299 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.22%
|
2,444,163
|
$4,839,444 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
2,382,503
|
$4,717,356 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.21%
|
2,333,333
|
$4,619,999 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.2%
|
2,230,112
|
$4,415,622 | — | 31 Dec 2025 | |
| Kercheville Advisors, LLC |
13F
|
Company |
0.05%
|
584,174
|
$4,287,837 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.18%
|
1,995,607
|
$3,951,301 | — | 31 Dec 2025 | |
| Voleon Capital Management LP |
13F
|
Company |
0.13%
|
1,514,586
|
$2,998,880 | — | 31 Dec 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.13%
|
1,494,713
|
$2,959,532 | — | 31 Dec 2025 | |
| David C. Sachs |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
340,794
mixed-class rows
|
$2,889,293 | — | 22 Feb 2026 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.12%
|
1,324,871
|
$2,616,620 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.11%
|
1,231,770
|
$2,438,905 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.11%
|
1,219,879
|
$2,415,361 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.1%
|
1,142,256
|
$2,261,667 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
882,327
|
$1,747,007 | — | 31 Dec 2025 | |
| Clearwater Capital Advisors, LLC |
13F
|
Company |
0.08%
|
845,084
|
$1,673,267 | — | 31 Dec 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.07%
|
766,908
|
$1,518,478 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.06%
|
704,574
|
$1,395,057 | — | 31 Dec 2025 | |
| ALLEN HOLDING INC /NY |
13F
|
Company |
0.06%
|
687,571
|
$1,361,391 | — | 31 Dec 2025 | |
| Accurate Wealth Management, LLC |
13F
|
Company |
0.05%
|
560,000
|
$1,304,800 | — | 31 Dec 2025 | |
| Swiss National Bank |
13F
|
Company |
0.06%
|
652,400
|
$1,291,752 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.06%
|
633,094
|
$1,253,526 | — | 31 Dec 2025 | |
| SHEETS SMITH WEALTH MANAGEMENT |
13F
|
Company |
0.06%
|
631,975
|
$1,251,311 | — | 31 Dec 2025 | |
| Sculptor Capital LP |
13F
|
Company |
0.06%
|
619,000
|
$1,225,620 | — | 31 Dec 2025 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.05%
|
607,330
|
$1,202,513 | — | 31 Dec 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.02%
|
196,200
|
$1,165,000 | — | 31 Dec 2025 | |
| John C. Thomas |
3/4/5
|
Former Director |
—
class O/S missing
|
216,363
|
$1,086,143 | — | 31 Dec 2021 | |
| Regan J. Lauer |
3/4/5
|
Chief Accounting Officer |
—
mixed-class rows
|
119,940
mixed-class rows
|
$1,035,917 | — | 22 Feb 2026 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.05%
|
515,920
|
$1,021,521 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.04%
|
493,445
|
$977,021 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.04%
|
461,176
|
$913,128 | — | 31 Dec 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.04%
|
458,059
|
$906,957 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for ImmunityBio, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Conversion of derivative security | 1.87% | 4,606,596 | 251,018,873 | 31 Mar 2026 | See footnote | ||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Soon Shiong Patrick | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Patrick Soon-Shiong | IBRX | Second Amended and Restated Convertible Promissory Note | Conversion of derivative security | 0 | $480,000,000 | 31 Mar 2026 | See footnote | |||
| Barry J. Simon | IBRX | Common Stock | Sale | -2.56% | -75,000 | 2,850,821 | 24 Feb 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Sale | -100% | $250,000 | $10.00 | -25,000 | 0 | 23 Feb 2026 | Direct |
| Christobel Selecky | IBRX | Common Stock | Options Exercise | 25,000 | 25,000 | 23 Feb 2026 | Direct | |||
| Christobel Selecky | IBRX | Stock Option (right to buy) | Options Exercise | -26.9% | -25,000 | 67,937 | 23 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Sale | -5.34% | $1,691,102 | $10.25 | -165,000 | 2,925,821 | 23 Feb 2026 | Direct |
| David C. Sachs | IBRX | Common Stock | Tax liability | -6.45% | -20,682 | 300,143 | 22 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Common Stock | Options Exercise | 14.5% | 40,650 | 320,825 | 22 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Restricted Stock Units | Options Exercise | -50% | -40,650 | 40,651 | 22 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Tax liability | -0.2% | -58,170 | 29,757,911 | 22 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Options Exercise | 0.38% | 114,329 | 29,816,081 | 22 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Restricted Stock Units | Options Exercise | -50% | -114,329 | 114,329 | 22 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Tax liability | -1.42% | -1,673 | 115,875 | 22 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Options Exercise | 3.58% | 4,065 | 117,548 | 22 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Restricted Stock Units | Options Exercise | -50% | -4,065 | 4,065 | 22 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Tax liability | -12.2% | -77,560 | 560,344 | 22 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Options Exercise | 31.4% | 152,439 | 637,904 | 22 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Restricted Stock Units | Options Exercise | -50% | -152,439 | 152,439 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Tax liability | -0.19% | -6,026 | 3,090,821 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Options Exercise | 0.49% | 15,243 | 3,096,847 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Restricted Stock Units | Options Exercise | -50% | -15,243 | 15,245 | 22 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Sale | -0.32% | $92,500 | $9.25 | -10,000 | 3,081,604 | 20 Feb 2026 | Direct |
| Patrick Soon-Shiong | IBRX | Common Stock | Tax liability | -0.4% | -118,560 | 29,701,752 | 10 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Common Stock | Options Exercise | 0.93% | 274,122 | 29,820,312 | 10 Feb 2026 | Direct | ||
| Patrick Soon-Shiong | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -274,122 | 548,246 | 10 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Common Stock | Tax liability | -13.2% | -42,643 | 280,175 | 10 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Common Stock | Options Exercise | 34.2% | 82,236 | 322,818 | 10 Feb 2026 | Direct | ||
| David C. Sachs | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -82,236 | 164,474 | 10 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Tax liability | -1.95% | -2,257 | 113,483 | 10 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Common Stock | Options Exercise | 4.97% | 5,482 | 115,740 | 10 Feb 2026 | Direct | ||
| Regan J. Lauer | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -5,482 | 10,965 | 10 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Tax liability | -22.4% | -140,048 | 485,465 | 10 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Common Stock | Options Exercise | 78% | 274,122 | 625,513 | 10 Feb 2026 | Direct | ||
| Richard Adcock | IBRX | Restricted Stock Units | Options Exercise | -33.3% | -274,122 | 548,246 | 10 Feb 2026 | Direct | ||
| Barry J. Simon | IBRX | Common Stock | Sale | -4.69% | -151,967 | 3,091,604 | 20 Jan 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Sale | -100% | -25,000 | 0 | 20 Jan 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Options Exercise | 25,000 | 25,000 | 20 Jan 2026 | Direct | |||
| Christobel Selecky | IBRX | Stock Option (right to buy) | Options Exercise | -21.2% | -25,000 | 92,937 | 20 Jan 2026 | Direct | ||
| Christobel Selecky | IBRX | Common Stock | Sale | -100% | $250,000 | $5.00 | -50,000 | 0 | 16 Jan 2026 | Direct |
| Christobel Selecky | IBRX | Common Stock | Options Exercise | 50,000 | 50,000 | 16 Jan 2026 | Direct | |||
| Christobel Selecky | IBRX | Stock Option (right to buy) | Options Exercise | -29.8% | -50,000 | 117,937 | 16 Jan 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.